Skip to main content
. 2021 Nov 18;22(22):12438. doi: 10.3390/ijms222212438

Figure 1.

Figure 1

The schedule for the establishment of DRM cells and cell viability of DRM cells with (A) MDA-MB-231 human breast cancer cells were treated with doxorubicin with the increasing concentration ranges from 10 nM to 100 nM. Based on the human plasma concentrations of doxorubicin, the final concentration (100 nM) was designed. The cells were treated and maintained with doxorubicin, and the number of passages is represented as P1, P2… Cells were maintained in doxorubicin-containing media for 38 weeks. (B) The cell viability assay for the three clones (22.5, 50 and, 100 nM DRM cells) that showed morphological changes while establishing doxorubicin-resistant cells. The cells showed resistance to doxorubicin as compared to parental cells. The values expressed as mean ± standard deviation (SD) (n = 5) (* p < 0.05 vs. control; ** p < 0.001 vs. control). DRM: Doxorubicin-resistant MDA-MB-231.